{"id":11651,"name":"NeoAntigen Treatment Navigator","purpose":"A software platform to help oncologists and researchers navigate the rapidly evolving landscape of individualized neoantigen cancer treatments, leveraging AI to analyze genomic data and predict treatment efficacy, based on Moderna's expansions.","profitable":1,"date_generated":"Friday April 2026 23:01","reference":"project-neoantigen-navigator","technology_advise":["Python","PostgreSQL","Difficult","Data"],"development_time_estimation_mvp_in_hours":220,"grade":8.2,"category":"healthcare","view_count":4,"similar_ideas":[{"id":11647,"name":"Neo-Antigen Therapy Risk Analyzer","grade":7.8,"category":"healthcare"},{"id":9220,"name":"NanoCancer Assist","grade":8.8,"category":"healthcare"},{"id":4971,"name":"Clinical Trial Signal Accelerator (CTSA)","grade":8.2,"category":"healthcare"},{"id":2811,"name":"Rare Disease Personalized Insights (RDPI)","grade":8.7,"category":null},{"id":1307,"name":"Assistive Tech Navigator","grade":7.8,"category":null}],"source_headline":"Moderna faces dilemma in naming next-gen mRNA treatments"}